Pandemic Darlings The pandemic economy, in original documents
Home Source documents Sorrento Therapeutics, Inc. Form 4 (Dec. 15, 2022)Search ⌕

Sorrento Therapeutics, Inc. Form 4 (Dec. 15, 2022)

Summary

Henry Ji, a director and officer of Sorrento Therapeutics, Inc. [SRNE] listed in the remarks as President, CEO and Chairman of the Board of Directors, reports on this Form 4 a restricted stock unit award for 1,500,000 shares dated December 15, 2022. A footnote states the compensation committee approved the award on September 1, 2022 and granted it on September 2, 2022, conditioned on stockholder approval of an amendment to the 2019 Stock Incentive Plan, which the stockholders approved on December 15, 2022. A footnote states 1/4th of the shares vests on September 2, 2023 and 1/4th on each anniversary thereafter. Directly owned shares after the award total 6,265,805. The form is signed /s/ Henry Ji, Ph.D. on 12/16/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Sorrento Therapeutics, Inc. Form 4 (Dec. 15, 2022).” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-4-filed2022-12-16-0001209191-22-061746-c12d1946bb/, SHA-256 d458d9121c4079f20b24d11f9737c6a5d672e1cdb6890025e8bea95c988f89bf.

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Ji Henry (Last) (First) (Middle) C/O SORRENTO THERAPEUTICS, INC. 4955 DIRECTORS PLACE (Street) SAN DIEGO CA 92121 (City) (State) (Zip) | Ji Henry | (Last) | (First) | (Middle) | C/O SORRENTO THERAPEUTICS, INC. | 4955 DIRECTORS PLACE | SAN DIEGO | CA | 92121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Sorrento Therapeutics, Inc. [ SRNE ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) See Remarks | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | See Remarks
3. Date of Earliest Transaction
 (Month/Day/Year) 12/15/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 12/15/2022 (1) | A | 1,500,000 (2) | A | $ 0.00 | 6,265,805 | D
Common Stock | 2,271,693 | I | See Footnote (3)
Common Stock | 40,000 | I | By spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
1. The grant to the Reporting Person of a restricted stock unit award for 1,500,000 shares of the Issuer's common stock (the "RSU Award") was approved by the compensation committee of the board of directors of the Issuer on September 1, 2022 and was granted to the Reporting Person on September 2, 2022. The RSU Award was conditioned upon and subject to the Issuer's stockholders approving an amendment to the Issuer's 2019 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder (the "Plan Amendment"). The Issuer's stockholders approved the Plan Amendment on December 15, 2022.
2. The reported securities are shares subject to the RSU Award. 1/4th of the shares subject to the RSU Award shall vest on September 2, 2023 and 1/4th of the shares
subject to the RSU Award shall vest on each anniversary thereafter.
3. Shares are held in family trusts of which the Reporting Person is a co-trustee with his spouse.
Remarks:
President, CEO and Chairman of the Board of Directors
/s/ Henry Ji, Ph.D. | 12/16/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File
SEC_SRNE_4_filed2022-12-16_0001209191-22-061746.xml
Size
16,994 bytes
SHA-256
d458d9121c4079f20b24d11f9737c6a5d672e1cdb6890025e8bea95c988f89bf
Our copy
SEC_SRNE_4_filed2022-12-16_0001209191-22-061746.xml
Original
www.sec.gov
Back to top